Five-Year Updates on Venetoclax + Obinutuzumab for Previously Untreated CLL: Clinical Learnings From the CLL14 Study
By
The University of Kansas Cancer Center
FEATURING
Marc Hoffmann
By
The University of Kansas Cancer Center
FEATURING
Marc Hoffmann
Login to view comments.
Click here to Login